![Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial | Nature Medicine Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial | Nature Medicine](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41591-022-02031-7/MediaObjects/41591_2022_2031_Fig1_HTML.png)
Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial | Nature Medicine
![Cambridge begins world-first COVID-19 vaccine booster study - NIHR - Cambridge Clinical Research Facility Cambridge begins world-first COVID-19 vaccine booster study - NIHR - Cambridge Clinical Research Facility](https://www.cambridgecrf.nihr.ac.uk/wp-content/uploads/2023/03/Peter_trial_vacinne_web.png)
Cambridge begins world-first COVID-19 vaccine booster study - NIHR - Cambridge Clinical Research Facility
![News - Major Covid-19 booster trial looks at how best to improve immunity against coronavirus in vulnerable people - University of Nottingham News - Major Covid-19 booster trial looks at how best to improve immunity against coronavirus in vulnerable people - University of Nottingham](https://www.nottingham.ac.uk/PressReleaseLongForm-Images/MHS/Vaccine-combo.xd02a85cc.jpg)
News - Major Covid-19 booster trial looks at how best to improve immunity against coronavirus in vulnerable people - University of Nottingham
![Moderna on X: "In a Phase 2/3 trial in over 500 adults, mRNA-1273.222, induced significantly higher neutralizing antibody titers against BA.4/BA.5 compared to a booster dose of mRNA-1273. Read more: https://t.co/CPnxL03nZW https://t.co/ODihw6qtsQ" / Moderna on X: "In a Phase 2/3 trial in over 500 adults, mRNA-1273.222, induced significantly higher neutralizing antibody titers against BA.4/BA.5 compared to a booster dose of mRNA-1273. Read more: https://t.co/CPnxL03nZW https://t.co/ODihw6qtsQ" /](https://pbs.twimg.com/media/Fhhqz2NWAAInpLU.jpg)
Moderna on X: "In a Phase 2/3 trial in over 500 adults, mRNA-1273.222, induced significantly higher neutralizing antibody titers against BA.4/BA.5 compared to a booster dose of mRNA-1273. Read more: https://t.co/CPnxL03nZW https://t.co/ODihw6qtsQ" /
![Global-first COVID-19 vaccine booster trial launches in Bradford – Bradford Teaching Hospitals NHS Foundation Trust Global-first COVID-19 vaccine booster trial launches in Bradford – Bradford Teaching Hospitals NHS Foundation Trust](https://www.bradfordhospitals.nhs.uk/wp-content/uploads/2021/06/vab.jpg)
Global-first COVID-19 vaccine booster trial launches in Bradford – Bradford Teaching Hospitals NHS Foundation Trust
![UC San Diego joins national trial to explore new vaccines for COVID-19 variants | University of California UC San Diego joins national trial to explore new vaccines for COVID-19 variants | University of California](https://www.universityofcalifornia.edu/sites/default/files/covid-vaccine-2022-trial.jpg)
UC San Diego joins national trial to explore new vaccines for COVID-19 variants | University of California
![Major COVID-19 booster trial looks at how best to improve immunity against coronavirus in vulnerable people | NIHR Major COVID-19 booster trial looks at how best to improve immunity against coronavirus in vulnerable people | NIHR](https://www.nihr.ac.uk/images/news/booster-hero-image.png)
Major COVID-19 booster trial looks at how best to improve immunity against coronavirus in vulnerable people | NIHR
![New global vaccine trial launched to evaluate fractional COVID-19 booster shots - Murdoch Children's Research Institute New global vaccine trial launched to evaluate fractional COVID-19 booster shots - Murdoch Children's Research Institute](https://www.mcri.edu.au/images/news/shutterstock_1935309334_indo_vaccination_centre.jpg)
New global vaccine trial launched to evaluate fractional COVID-19 booster shots - Murdoch Children's Research Institute
![Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial | Nature Medicine Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial | Nature Medicine](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41591-022-01739-w/MediaObjects/41591_2022_1739_Fig1_HTML.png)
Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial | Nature Medicine
![Vaccine trial to investigate a booster for teenagers to protect against COVID-19 | Health Care Research Wales Vaccine trial to investigate a booster for teenagers to protect against COVID-19 | Health Care Research Wales](https://healthandcareresearchwales.org/sites/default/files/styles/large/public/2022-05/Patient_arm_vaccination.jpg?h=cea2b766&itok=khadLf6F)
Vaccine trial to investigate a booster for teenagers to protect against COVID-19 | Health Care Research Wales
![Safety and immunogenicity of seven COVID-19 vaccines as a third dose ( booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV- BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial - Safety and immunogenicity of seven COVID-19 vaccines as a third dose ( booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV- BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial -](https://www.thelancet.com/cms/attachment/966d70c5-8395-4ea2-9a35-94dc18f2f550/gr1.gif)